The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Wed., Aug. 31, 12:13 AM

Slide #5. OncoMed Pharmaceuticals, Inc. Secondary Offering

Company: OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED)
Date announced: 8/17/2016
Shares Offered: 5,500,000
Date of Pricing: 8/18/2016
Price Per Share: $10.00
Secondary Offering Details: OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by OncoMed. In addition, OncoMed intends to grant to the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering, on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed. -updated 8/18- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $10.00 per share. Net proceeds to OncoMed from this offering are expected to be approximately $51.4 million after underwriting discounts and commissions and estimated offering expenses. The offering is expected to close on or about August 23, 2016, subject to customary closing conditions. The Company has granted the underwriters of the offering the right for a period of 30 days to purchase up to an additional 825,000 shares of common stock at the public offering price, less underwriting discounts and commissions.

OncoMed Pharmaceuticals is a clinical development-stage biopharmaceutical company focused on discovering and developing anti-cancer stem cell and immuno-oncology therapeutics. Co. has seven product candidates in clinical development including: demcizumab for non-small cell lung cancer; tarextumab for small cell lung cancer patients; vantictumab for breast cancer and pancreatic cancer; ipafricept for pancreatic cancer and ovarian cancer; brontictuzumab for solid tumor patients; anti-DLL4/VEGF bispecific for patients with advanced solid tumors; and anti-RSPO3 for solid tumor patients and metastatic colorectal cancer patients.

OMED SEC Filing Email Alerts Service

Open the OMED Page at The Online Investor »

Company Name:  OncoMed Pharmaceuticals Inc.
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding OMED:  16
Total Market Value Held by ETFs:  $9.40M
Total Market Capitalization:  $318.00M
% of Market Cap. Held by ETFs:  2.96%

Open the OMED Page at The Online Investor (in a new window) »

August 31, 2016    12:13 AM Eastern
Quotes delayed 20 minutes

Strong Buy (3.71 out of 4)
79th percentile
(ranked higher than approx. 79% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.